INVITRO ANTITUMOR-ACTIVITY OF TENIPOSIDE AGAINST CARCINOMA OF THE LUNG IN HUMAN-TUMOR CLONOGENIC-ASSAY

  • 1 September 1986
    • journal article
    • research article
    • Vol. 6  (5) , 921-924
Abstract
The antitumor activity of teniposide (VM26) on carcinoma of the lung was tested by comparing it with its congener, etoposide (VP16) in an in vitro soft agar clonogenic assay system (HTCA). Of 56 tumor biopsies placed in culture, 40 tumors were evaluable for drug sensitivity information (i.e., .gtoreq. 30 colonies in the control plate). The overall in vitro response rate (defined as .ltoreq. 50% survival of TCFU) at the standard dose (10% peak plasma concentration) was 35%, which is higher than that of VP16 (28%). In cell lines derived from human carcinoma of the lung, VM26 showed 50% inhibition against colony formation of PC-7 cells at 0.45 .mu.g/ml which is less than that of VP16. A superior antitumor activity of VM26 on PC-9 cells was also observed. VM26 was observed to act faster than VP16 thus indicating its possible superior antitumor activity in vivo.